Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04260256 · ClinicalTrials.gov registry record · Phase 2
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
A Phase 2 study of Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit, sponsored by CellSight Technologies.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT04260256: Recruiting Phase 2 study of Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit, sponsored by CellSight Technologies.
NCT04260256 is a Phase 2 study of Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit that is actively recruiting participants, run by CellSight Technologies. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04260256, a Phase 2 study of Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit, is actively recruiting participants, sponsored by CellSight Technologies.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this study, patients with advanced solid tumors will undergo \[18F\]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.
Primary Outcome
Pre and post CkIT biopsies of the same tumor lesion will be performed an analyze T-cell tumor infiltration, this will be correlated to \[18F\]F-AraG PET signal.
Conditions Studied
Interventions
- DRUG [18F]F-AraG
Study Locations (2)
California
- Stanford University - Stanford
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 2 |
What NCT04260256 shows while recruiting
NCT04260256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit appearing as the primary indexed condition, and to 1 intervention - of which [18F]F-AraG is the first listed.
NCT04260256 reports a single indexed study location in California, Oregon.
Frequently Asked Questions
What is clinical trial NCT04260256 about?
NCT04260256 is a clinical study titled "A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors". In this study, patients with advanced solid tumors will undergo \[18F\]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.
What is the current status of trial NCT04260256?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-03-01. Estimated completion is 2026-11-30.
What conditions does trial NCT04260256 study?
This clinical trial studies the following conditions: Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit.
What interventions are being tested in trial NCT04260256?
The interventions under investigation include: [18F]F-AraG (DRUG).
Who is sponsoring clinical trial NCT04260256?
This trial is sponsored by CellSight Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04260256 being conducted?
This trial has 2 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04260256's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI